$12.80
0.221.75%
Last update: Nov 4, 4:05 PM
Kailera Therapeutics Inc (KLRA) Stock Price, Quote, News & History
KLRANASDAQ
Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.
You can purchase shares of Kailera Therapeutics (NASDAQ:KLRA) through any online brokerage.
Other companies in Kailera Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Kailera Therapeutics has a consensus price target of $38.00.
The stock price for Kailera Therapeutics (NASDAQ: KLRA) is $12.74 last updated November 4, 2026 at 4:05 PM EST.
There are no upcoming dividends for Kailera Therapeutics.
Kailera Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Kailera Therapeutics.
Kailera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates,...
